StockData
GRAIL, Inc. logo

GRAIL, Inc. (GRAL) stock

GRALNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30
$102.10−3.78 (-3.57%)

Close on Nov 18, 2026Market cap $4.56BP/E –Yield –

Grail operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Grail's operating income for the twelve months ending Jun 30, 2026 was -$559.25M. For fiscal 2025 it was -$562.16M.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$562.16M–
FY2024Dec 31, 2024-$2.19B–
FY2023Dec 31, 2023-$1.52B–
FY2022Jan 1, 2023-$5.44B–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$173.78M–
Q1 FY2026Mar 31, 2026-$135.77M–
Q4 FY2025Dec 31, 2025-$124.41M–
Q3 FY2025Sep 30, 2025-$125.29M–
Q2 FY2025Jun 30, 2025-$158.85M–
Q1 FY2025Mar 31, 2025-$153.61M–
Q4 FY2024Dec 31, 2024-$136.94M–
Q3 FY2024Sep 30, 2024-$183.51M–
Q2 FY2024Jun 30, 2024-$1.64B–
Q1 FY2024Mar 31, 2024-$227.42M–
Q4 FY2023Dec 31, 2023-$194.59M–
Q3 FY2023Oct 1, 2023-$912.39M–
Q2 FY2023Jun 30, 2023-$204.37M–

More Grail figures

See a number that looks wrong?